Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain
NCT ID: NCT02985216
Last Updated: 2019-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
371 participants
INTERVENTIONAL
2017-02-07
2018-05-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin
NCT02783183
Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
NCT00219544
A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients
NCT00654940
Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
NCT01455428
PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers
NCT02783638
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
YHD1119
YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150\~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.
YHD1119
YHD1119 150mg, PO YHD1119 300mg, PO
YHD1119 600mg, PO
Lyrica
Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150\~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.
Lyrica
Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YHD1119
YHD1119 150mg, PO YHD1119 300mg, PO
YHD1119 600mg, PO
Lyrica
Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c ≤ 9.5% diabetes mellitus patients with pain over 6 months in Diabetic Peripheral Neuropathy or postherpetic Neuralgia patients at least 3 months pain after diagnosis of skin rash due to herpes zooster
Exclusion Criteria
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yuhan Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yong Chul KIM, M.D.,Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Seoul National University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yong Chul Kim
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YHD1119-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.